This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Celgene antitrust probe closed by Brazil's CADE

( February 28, 2023, 16:52 GMT | Official Statement) -- MLex Summary: A Brazilian investigation into US pharmaceutical company Celgene for allegedly creating barriers to competition, foreclosing the market and abusing its intellectual property rights in the medicines market has been closed. The Administrative Council for Economic Defense, or CADE, started the investigation after a complaint by pharmaceutical firm Eurofarma. In its decision closing the probe, which involves Celgene's Revlimid, a medicine used for cancer treatment, CADE found that there's no refusal to contract by Celgene, nor is there any abuse of intellectual property. Finally, CADE said the lawsuits filed by Celgene against Eurofarma before courts involve private interests.CADE statement and decision follow in Portuguese:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections